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Abstract: Purpose
Metabolic Syndrome (MetS) augments the incidence of cardiovascular disease by 2-
fold and type II diabetes mellitus by 5-fold. Montmorency tart cherries are rich in
phytochemicals shown to improve biomarkers related to cardio-metabolic health in
humans. This study aimed to examine cardio-metabolic responses after 7 days
Montmorency tart cherry juice (MTCJ) supplementation and also acute on short-term
supplementation responses to a single-bolus, in humans with MetS.
Methods
In a randomised, single-blind, placebo-controlled, crossover trial, twelve participants
with MetS (50 ±10 years; 6M/6F), consumed MTCJ or placebo (PLA) for 7 days. Blood-
based and functional cardio-metabolic biomarkers were measured pre- and post-
supplementation, and acute responses measured pre-bolus and up to 5 hours post-
bolus on the 7  th  day.
Results
24-hour ambulatory systolic (  P  = 0.016), diastolic (  P  = 0.009) blood pressure and
mean arterial pressure (  P  = 0.041) were significantly lower after 7 days MTCJ
supplementation compared to PLA. Glucose (  P  = 0.038), total cholesterol (  P  =
0.036), LDL (  P  = 0.023) concentrations, total cholesterol:HDL ratio (  P  = 0.004) and
respiratory exchange ratio values (  P  = 0.009) were significantly lower after 6 days
MTCJ consumption compared to PLA.
Conclusions
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
This study revealed for the first time in humans that MTCJ significantly improved 24-
hour BP, fasting glucose, total cholesterol and total cholesterol:HDL ratio, and also
lower resting respiratory exchange ratio compared to a control group. Responses
demonstrated clinically relevant improvements on aspects of cardio-metabolic function,
emphasising the potential efficacy of MTCJ in preventing further cardio-metabolic
dysregulation in participants with MetS. Registered at clinicaltrials.gov (NCT03619941).
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Purpose: Metabolic Syndrome (MetS) augments the incidence of cardiovascular disease by 6 
2-fold and type II diabetes mellitus by 5-fold. Montmorency tart cherries are rich in 7 
phytochemicals shown to improve biomarkers related to cardio-metabolic health in humans. 8 
This study aimed to examine cardio-metabolic responses after 7 days Montmorency tart 9 
cherry juice (MTCJ) supplementation and also acute on short-term supplementation 10 
responses to a single-bolus, in humans with MetS. Methods: In a randomised, single-blind, 11 
placebo-controlled, crossover trial, twelve participants with MetS (50 ±10 years; 6M/6F), 12 
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ratio (P = 0.004) and respiratory exchange ratio values (P = 0.009) were significantly lower 19 
after 6 days MTCJ consumption compared to PLA. Conclusions: This study revealed for the 20 
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1. Introduction 79 
The prevention of cardiovascular disease (CVD)1and type II diabetes mellitus (T2D) would be 80 
a major step in retarding the current exponential rise in global prevalence and incidence rates  81 
[1,2]. Metabolic Syndrome (MetS) augments the incidence of CVD by 2-fold and T2D by 5-82 
fold [3]. Dietary interventions to prevent and mitigate MetS are sought after as they can 83 
conveniently be implemented into an individual’s lifestyle. Anthocyanins, a sub-class of 84 
polyphenols, and their metabolites possess potent anti-oxidative and anti-inflammatory 85 
properties and have been shown to improve MetS symptoms [4]. Furthermore, Naseri et al. 86 
(2018) [5] reported improvements in cardio-metabolic function after consumption of 87 
anthocyanin-rich interventions in humans with MetS. Montmorency tart cherries are rich in 88 
phytochemicals including anthocyanins, however their bioefficacy may be attributed to 89 
downstream metabolites and synergisms with other nutrients within the fruit, which may also 90 
induce health benefits [6–9]. Insulin resistance is key to the underlying pathophysiology of 91 
MetS and anthocyanin-mediated improvements in insulin and glucose metabolism [10] may 92 
ameliorate many of its associated symptoms [11]. Willems et al. (2017) [12] reported 7 days 93 
continuous consumption of anthocyanin-rich New Zealand blackcurrant powder (NZBP) likely 94 
increased insulin sensitivity in healthy individuals. 95 
Acute supplementation of tart [8,13] and sweet [14] cherry juice has been shown to induce 96 
clinically-relevant reductions in SBP at 2-hours post-consumption, due to the pharmacokinetic 97 
profile and heightened bioavailability of MTC anthocyanins [15] and secondary metabolites 98 
[6]. A caveat of recommending MTCJ as an intervention for managing hypertension is that 99 
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greater clinical evidence is required which can be applied to normal daily-living conditions 100 
such as 24-hour ambulatory blood pressure monitoring (ABPM). The mechanism of action for 101 
the hypotensive properties of tart and sweet cherries has yet to be elucidated, with nitric oxide 102 
bioavailability [7] and modulation of arterial stiffness [7,13,16] not significantly changing after 103 
MTCJ consumption. Therefore, an alternative mechanism involving angiotensin-I-converting 104 
enzyme (ACE) was hypothesised in the present study, since Kirakosyan et al. (2018) [9] 105 
observed 88.7% ACE inhibition in vitro with Montmorency tart cherry (MTC) extract. The 106 
effect of MTC on ACE has not yet been assessed ex vivo in humans, therefore this mechanism 107 
warrants exploration in a human randomised controlled trial. 108 
The present study aimed to be the first to examine cardio-metabolic responses after short-term, 109 
continuous MTCJ supplementation (6 days) and acute responses to a single-bolus on the 7th 110 
day following short-term supplementation, in humans with MetS. It was hypothesised that 111 
MTCJ would improve glycaemic and insulinaemic function through increasing insulin 112 
sensitivity. Moreover, MTCJ would maintain acute reductions in SBP and lower 24-hour SBP 113 
after 7 days supplementation, through ACE inhibition.  114 
2. Methods 115 
2.1. Participants 116 
Twelve (6 males and 6 post-menopausal females) participants [mean ± SD, age 50 ± 10 years 117 
(range 28-62 years), stature 1.73 ± 0.12 m, body mass 94.1 ± 23.1 kg, body mass index 31 ± 7 118 
kg.m-2] with MetS (Tables 1A and 1B) volunteered for this study. All participants were 119 
screened for MetS prior to formal inclusion onto the study according to the harmonised criteria 120 
outlined by Alberti et al. (2009) [17], where 3 of the 5 qualifying criteria [Waist Circumference: 121 
ethnicity and sex specific criteria; Fasting Triglycerides: ≥1.69 mmol.L-1; Fasting High-122 
Density Lipoprotein: <1.03 mmol.L-1 (men), <1.29 mmol.L-1 (women); Blood Pressure: ≥130 123 
mmHg SBP or ≥85 mmHg diastolic blood pressure (DBP); Fasting Glucose: ≥5.6 mmol.L-1] 124 
had to be met. Recruitment (Figure 1) was conducted via word of mouth, flyers and email 125 
advertisements. Participants were excluded from the study if they did not meet the criteria for 126 
MetS at screening, were smokers, pregnant, heavy alcohol consumers (>14 units per week), 127 
current or previous diagnosis of chronic disease (gastrointestinal, cardiovascular, hepatic or 128 
renal), or were on statins, hyperlipidaemic, anti-hypertensive, anti-diabetic, anti-inflammatory 129 
or steroidal medication. All participants were instructed to abstain from consuming any other 130 
multivitamin, anti-oxidant, fish oil, dietary or herbal supplementation two weeks prior to and 131 
for the duration of the study. Verbal and written information was provided to all participants 132 
regarding the study purpose and procedures. Ethical approval was obtained from the University 133 
of Hertfordshire HSET Ethics Committee (LMS/PGR/UH/03319) and the study’s experimental 134 
procedures followed the principles outlined in the Declaration of Helsinki. Written informed 135 
consent was provided by all participants prior to enrolment. This study was registered as a 136 
clinical trial on clinicaltrials.gov (NCT03619941). ***Table 1A and 1B near here***137 
***Figure 1 near here*** 138 
2.2 Procedures 139 
2.2.1. Research Design 140 
A single-blind (blinded to participant), placebo-controlled, randomised, crossover design was 141 
utilised; each participant acted as their own control. During the 6-week study duration, 142 
participants completed both testing sessions during which placebo (PLA) or Montmorency Tart 143 
Cherry Juice (MTCJ) supplements were consumed for a continuous period of 7 days. A 14-day 144 
washout period [8] was incorporated prior to crossover to the opposing condition.  145 
Schematics are shown of the overall study design (Figure 2A) and specific procedures during 146 
a testing session. The first and third testing sessions lasted 1 hour; pre-supplementation 147 
anthropometric (stature, body mass, waist circumference), functional [pulse wave analysis 148 
(PWA), cardiac haemodynamics, resting metabolic rate (RMR)] and fasting blood-based 149 
biomarkers were measured. Testing sessions two and four lasted 6 hours; anthropometric, 150 
functional and fasting blood-based biomarkers were measured prior to consumption of the 151 
supplement (6 days post-supplementation) and up to 5-hours post-consumption of the 7th bolus 152 
(Figure 2B). Testing sessions two and four were conducted following 6 days short-term 153 
supplementation of either MTCJ or PLA, during which the 7th bolus of supplement was 154 
consumed, and acute measurements taken thereafter which we have termed acute on short-term 155 
supplementation (Figure 2A). 156 
 157 
***Figure 2 near here***158 
2.2.2. Dietary Guidelines 159 
All participants arrived at the laboratory between 7 – 10am, after an overnight fast of a 160 
minimum of 10 hours, to account for circadian variation. Participants were instructed to 161 
maintain their habitual polyphenol intake, including anthocyanins, as opposed to complete 162 
restriction throughout the study. This was to ensure that the polyphenols provided by MTCJ 163 
were supplementary to the existing habitual polyphenol intake of each participant 164 
representing normal daily activity and therefore upholding ecological validity.  165 
Total energy, macronutrient and polyphenol intake of participants’ ‘Western’ habitual diet was 166 
analysed through food diaries. This was to assess compliance of replicating dietary intake for 167 
the 3 days prior to each testing session. Dietary analysis software (Dietplan 7.0, Forestfield 168 
Software, UK) was used to monitor compliance of the 3-day food diaries for macronutrient, 169 
polyphenol and anthocyanin intake, before each session. All participants complied with dietary 170 
guidelines upon analysis for percentage contributions of macronutrients to total energy intake 171 
[(protein 14 ± 22%), (carbohydrate 48 ± 40%), (fat 38 ± 41%)], total polyphenols (62 ± 70 mg) 172 
and anthocyanins (20 ± 17 mg). 173 
2.2.3. Supplementation 174 
This study acutely administered two different supplements including a placebo which acted 175 
as the control condition and one experimental condition, MTCJ. MTCJ consisted of 30 mL 176 
Montmorency tart cherry concentrate (Cherry Active, Active Edge Ltd, Hanworth, UK) 177 
diluted in 100 mL water. It was identified that the concentrate contained glucose (55.73% of 178 
total sugars) and fructose (44.27% of total sugars). The 30 mL serving of Montmorency tart 179 
cherry concentrate contained ~90-110 whole Montmorency tart cherries. The placebo was 180 
composed of 30 mL commercially available fruit-flavoured cordial (Cherries and Berries, 181 
Morrisons, Bradford, UK) mixed with 100 mL water. The placebo drink was matched against 182 
MTCJ for percentage contribution of carbohydrate to total energy and contribution of sugars 183 
to total carbohydrate, energy content, taste and visual appearance by adding dextrose (My 184 
Protein Ltd, Northwich, UK), fructose (Fruit Sugar, Morrisons, Bradford, UK), cornflour 185 
(Morrisons, Bradford, UK), citric acid (100% Pure Citric Acid, VB and Sons, UK), red and 186 
black food colouring (Morrisons, Bradford, UK). Nutritional analysis for MTCJ (Volume: 187 
130 mL, Energy: 102 kcal, Carbohydrates: 24.5 g of which Sugars: 17.9 g, Glucose: 9.98 g, 188 
Fructose: 7.92 g, Protein: 1.1 g, Fat: 0 g, Fibre: 2.6 g, Total Anthocyanins: 270 mg) and 189 
placebo (Volume: 130 mL, Energy: 102 kcal, Carbohydrates: 25 g of which Sugars: 18 g, 190 
Glucose: 10.03 g, Fructose: 7.97 g, Protein: 0.5 g, Fat: 0 g, Fibre: Trace, Total Anthocyanins: 191 
0 mg). Anonymity of the supplementation was ensured by blinding the participants to the 192 
source of anthocyanins. This was achieved by explaining that an ‘anthocyanin-rich 193 
supplement’ would be provided rather than disclosing Montmorency tart cherries as the 194 
specific source. Only 2/12 participants correctly distinguished the supplements provided 195 
(intervention or placebo) and none identified the intervention as ‘cherry’ or ‘containing 196 
cherries (either sweet or tart)’. 197 
2.2.4. Measures and Equipment 198 
Serum insulin was regarded as the primary endpoint for the present study. HOMA2-IR, acute 199 
SBP and 24-hour SBP were regarded as secondary variables. Tertiary endpoints focused on 200 
other aspects of MetS including hyperlipidaemia, hyperglycaemia and cardiovascular 201 
dysfunction. 202 
Blood pressure, cardiac haemodynamics and PWA measurements were all conducted in a quiet, 203 
temperature-controlled laboratory maintained between 21-24ºC. All measurements were 204 
performed in an upright seated position with 10 minutes prior rest. 205 
2.2.4.1. Blood Pressure 206 
Brachial systolic (SBP) and diastolic (DBP) blood pressure (Omron MX3, Omron, Japan) 207 
were measured four times, with an average of the final three being taken as BP. 208 
2.2.4.2. Cardiac Haemodynamics 209 
Beat-to-beat resting cardiac haemodynamic parameters including heart rate (HR), cardiac 210 
output (CO), stroke volume (SV), mean arterial pressure (MAP) and total peripheral 211 
resistance (TPR) were measured non-invasively (Finometer MIDI Model-2, Finapres Medical 212 
Systems BV, Amsterdam, The Netherlands) at all time points, using the arterial volume 213 
clamp method.  214 
2.2.4.3. 24-hour Ambulatory Blood Pressure 215 
In addition to clinic BP measurements in the laboratory using an automated 216 
sphygmomanometer, 24-hour ambulatory blood pressure monitoring (ABPM) (Meditech 217 
ABPM-04, Meditech, Hungary) was also conducted through an oscillometric method. ABPM-218 
04 monitors have been clinically validated against British Hypertension Society guidelines 219 
[18]. ABPM provides a more accurate representation of BP as measurements are obtained 220 
under normal daily-living conditions, negating white coat syndrome; and mean pressures are 221 
taken from multiple readings over a 24-hour period, thus ABPM has become the reference 222 
standard for measuring BP non-invasively and diagnosing hypertension [19]. Moreover, 24-223 
hour ABPM is deemed to be the reference standard for accurate assessment of cardiovascular 224 
risk in adults [19].  225 
Participants underwent a familiarisation period of wearing the ABPM device prior to data 226 
collection. A day before and after the 7-day supplementation period, participants were fitted 227 
with a 24-hour ABPM on the non-dominant arm. The ABPM was programmed (CardioVisions 228 
Software 1.15.2, Meditech, Hungary) to take readings every 30 minutes during the day (07:00-229 
22:00) and every hour during the night (22:00-07:00) [20]. A minimum of 14 day-time readings 230 
and 7 night-time readings were considered for a valid 24-hour ABPM assessment [21]. 231 
Participants were advised to be seated upright, keep still and relax their arm whenever the 232 
monitor recorded measurements. The following data was obtained from the ABPM monitor: 233 
mean 24-hour, day-time and night-time SBP, DBP, MAP and PP. The difference between mean 234 
day and night SBP, DBP, MAP and PP was also calculated. 235 
2.2.4.4. Pulse Wave Analysis 236 
Aortic pulse waveforms, aortic SBP, aortic DBP, pulse pressure (PP), augmentation pressure 237 
(AP), augmentation index (AIx), AIx normalised to 75 beats.min-1 (AIx at HR75) and 238 
subendocardial viability ratio (SEVR) were determined by pulse wave analysis (PWA) using 239 
applanation tonometry (SphygmoCor, ScanMed Medical, UK) as previously described in 240 
[13]. 241 
2.2.4.5. Resting Metabolic Rate (RMR) 242 
RMR, resting energy expenditure (EE), substrate oxidation rates and respiratory exchange 243 
ratio (RER) were measured using an open-circuit indirect calorimetry system (GEM Nutrition 244 
Ltd, Cheshire, UK) as previously described in [13].  245 
Resting EE was determined by application of the Weir equation [22] below. 246 
Energy Expenditure (kcal.day-1) = [(3.94 * V̇O2) + (1.106 * V̇CO2)] * 1.44   247 
Equations outlined by Frayn (1983), were used to determine fat oxidation and carbohydrate 248 
(CHO) oxidation rates at rest. 249 
Fat Oxidation Rate (g.min-1) = (1.67 * V̇O2) – (1.67 * V̇CO2)     250 
Carbohydrate Oxidation Rate (g.min-1) = (4.55 * V̇CO2) – (3.21 * V̇O2)    251 
2.2.5. Blood Sampling and Analysis 252 
2.2.5.1. Blood Sampling 253 
Venous blood was sampled through 4 individual venepunctures (one at each time point: pre-254 
bolus and 1, 3, 5 hours post-bolus), using the butterfly method (BD Vacutainer Safety-Lok 255 
Blood Collection Set 21G with Luer Adapter, Becton Dickinson and Co., Oxford, UK). 256 
Tubes were centrifuged at 4000 rev.min-1, 4°C for 10 minutes (Sorvall ST 8R, Thermo Fisher 257 
Scientific, USA). Serum supernatants were aliquoted and stored at -80°C for later analysis. 258 
2.2.5.2. Glucose 259 
Serum samples were assessed for glucose (range 0.5-50 mmol.L-1, coefficient of variation 260 
(CV) ≤ 1.5%) (Biosen C-Line, EKF Diagnostics, Cardiff, UK) in duplicates.  261 
2.2.5.3. Insulin 262 
Serum insulin samples were measured in duplicates using a human 96-well colorimetric 263 
insulin enzyme-linked immunosorbent assay (ELISA) (Insulin Human ELISA KAQ1251, 264 
Invitrogen, Thermo Fisher Scientific, USA). Inter- and intra-plate precision were 6.1% and 265 
5.5%, respectively. 266 
2.2.5.4. Insulin Resistance and Sensitivity Indexes 267 
Homeostatic Model Assessment (HOMA) was used to estimate fasting steady-state 268 
pancreatic β-cell function (HOMA2-β), insulin sensitivity (HOMA2-%S) and insulin 269 
resistance (HOMA2-IR index) through the HOMA2 spreadsheet model (HOMA2-IR, 270 
available from https://www.dtu.ox.ac.uk/homacalculator/) [24].  271 
2.2.5.5. Lipid Assays 272 
Serum lipids were determined in duplicates using commercially available colorimetric assays 273 
on a semi-automated spectrophotometer (RX monza, Randox Laboratories Ltd, Antrim, UK), 274 
according to manufacturer’s guidelines. Triglyceride (Triglycerides TR210, Randox) values 275 
were corrected for free glycerol by subtracting 0.11 mmol.L-1, according to the 276 
manufacturer’s guidelines. Intra-assay CV for triglycerides, total cholesterol and HDL were 277 
2.94%, 4.45% and 4.22%, respectively. LDL was determined indirectly using the formula 278 
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2.2.5.6. Angiotensin-I-converting Enzyme 281 
Human ACE (CD 143) (peptidyl-dipeptidase A, EC 3.4.15.1) protein concentrations were 282 
measured according to manufacturer’s guidelines, from serum samples in duplicates using a 283 
96-well ELISA [Human ACE ELISA (CD 143) ab119577, Abcam, Cambridge, UK]. Inter- 284 
and intra-plate precision were 12.3% and 9.2%, respectively.  285 
2.3. Data Analysis 286 
Statistical analysis was performed using SPSS v22.0 (IBM, Chicago, USA) where data are 287 
reported as means ±standard deviation (±SD). Data normality was checked using a Shapiro-288 
Wilk test. Greenhouse-Geisser correction was applied upon violation of Mauchly’s test of 289 
sphericity for ANOVAs (P < 0.05). Statistical significance was set at P < 0.05. Based on data 290 
from Desai et al. (2019) [13] for the interaction effect between condition (PLA and MTCJ) and 291 
time for serum insulin, a priori power (α = 0.05; 1-β = 0.8) analysis indicated a sample size of 292 
8 would be sufficient to detect a significant difference pre-post 6 days supplementation for 293 
serum insulin. Therefore, a minimum of 12 participants were recruited assuming a 20% dropout 294 
rate. Post-hoc power analysis indicated sufficient power (1-β = 0.99; α = 0.05; n = 12) to detect 295 
a significant main effect for the interaction between condition and time (pre-post 6 days 296 
supplementation) for insulin, HOMA2-IR and 24-hour SBP. Acute SBP also demonstrated 297 
sufficient power (1-β = 0.86; α = 0.05; n = 12) to detect a significant interaction effect. 298 
A within-group two-way, 2 x 2, condition (PLA vs MTCJ) x time (Pre-Supplementation and 299 
Post-Supplementation), repeated-measures ANOVA design with post-hoc Bonferroni 300 
adjustment, measured differences for all blood-based biomarkers, cardiac haemodynamic, 301 
PWA, RMR and 24-hour BP parameters.  302 
To account for day-to-day physiological variances at pre-bolus between conditions for each 303 
variable, data were analysed as change from pre-bolus for each time point measured post-bolus 304 
during testing sessions 2 and 4. This enabled a fair assessment of the post-bolus responses to 305 
each condition, from pre-bolus across all variables. The pre-bolus time point was not included 306 
as a covariate, as one-way ANOVA analysis indicated no significant differences (P > 0.05) 307 
between conditions for all variables at the pre-bolus time point, hence two-way repeated-308 
measures ANOVA was performed.  A within-group two-way, 2 x 6, condition (PLA vs MTCJ) 309 
x time (30 minutes, 1, 2, 3, 4- and 5-hours post-bolus), repeated-measures ANOVA design with 310 
post-hoc Bonferroni adjustment, measured differences of cardiac haemodynamic, PWA and 311 
RMR parameters on change from pre-bolus values. Blood-based biomarkers were analysed 312 
using the same model but with a 2 x 3, condition (PLA vs MTCJ) by time (1, 3- and 5-hours 313 
post-bolus) design on change from pre-bolus values for each condition.  314 
Partial Eta-Squared (
2
partial ) was used to report effect sizes for ANOVA where effects were 315 
classified as small (0.01-0.08), moderate (0.09-0.25) and large (>0.25) [26]. Cohen’s d effect 316 
size was used for paired-samples t-test and post-hoc interaction comparisons where effects 317 
were classified as no effect (0-0.1), small (0.2-0.4), moderate (0.5-0.7) and high (≥0.8) [26]. 318 
3. Results 319 
3.1. Blood Biomarkers 320 
3.1.1. Glucose 321 
Responses to glucose pre and post 6 days supplementation (Figure 3) demonstrated a 322 
significant interaction effect (F(1, 11) = 5.534; P = 0.038, 
2
partial  = 0.34) and main effect for 323 
time (F(1, 11) = 8.077; P = 0.016, 
2
partial  = 0.42) only. Post-hoc indicated a significant difference 324 
between PLA and MTCJ at pre-supplementation time point (P = 0.023; d = 2.85). Fasting 325 
glucose was significantly (t(11) = 3.506; P = 0.005, d = 0.56) lower 6 days after supplementation 326 
(5.39 ± 0.23 mmol.L-1) compared to pre-supplementation (5.90 ± 0.86 mmol.L-1) with MTCJ. 327 
Individual responses showed 10/12 individuals with lower fasting glucose after 6 days 328 
supplementation of MTCJ compared to PLA. 329 
A main effect for time was found for change from pre-bolus data for glucose (F(2, 22) = 12.641; 330 
P < 0.001, 
2
partial  = 0.54) (Table 2). Post-hoc showed glucose to be significantly higher at 1-331 
hour post-bolus compared to both 3-hours (P = 0.003, d = 1.11) and 5-hours post-bolus (P = 332 
0.021, d = 0.92). 333 
3.1.2. Insulin 334 
Insulin responses to 6 days supplementation (Figure 3) only showed a significant interaction 335 
effect (F(1, 11) = 7.293; P = 0.021, 
2
partial  = 0.40). Pairwise comparisons indicated a significant 336 
difference between PLA and MTCJ at pre-supplementation time point (P = 0.049; d = 0.41). 337 
However, physiological responses showed after 6 days the mean change pre- to post-338 
supplementation was 27.05 ± 42.42 pmol.L-1 with PLA and -12.42 ± 30.50 pmol.L-1 with 339 
MTCJ. Moreover, individual responses showed 10/12 individuals with lower fasting insulin 340 
after 6 days supplementation of MTCJ compared to PLA, indicating a tendency for lower 341 
fasting insulin after MTCJ consumption compared to PLA. 342 
Similar to glucose, serum insulin only demonstrated a main effect of time (F(2, 22) = 16.828; P 343 
< 0.001, 
2
partial  = 0.61) on change from pre-bolus data (Table 2). Post-hoc showed insulin to 344 
be significantly higher at 1-hour post-bolus compared to both 3-hours (P = 0.005, d = 1.27) 345 
and 5-hours post-bolus (P = 0.004, d = 1.34). 346 
*** Table 2 near here***347 
3.1.3. HOMA2 348 
As with insulin, HOMA2-IR (F(1, 11) = 8.115; P = 0.016, 
2
partial  = 0.43) and HOMA2-%S (F(1, 349 
11) = 6.332; P = 0.029, 
2
partial  = 0.37) demonstrated a significant interaction after 6 days 350 
supplementation (Figure 3), with pairwise comparisons showing a significant difference 351 
between PLA and MTCJ at pre-supplementation time point for HOMA2-IR (P = 0.039; d = 352 
0.43). Individual responses for HOMA2-IR showed insulin resistance increased in 10/12 353 
participants with PLA, whereas insulin resistance was reduced in 8/12 participants after 6 days 354 
MTCJ consumption. Moreover, HOMA2-%S showed 9/12 participants increased insulin 355 
sensitivity with 6 days continuous MTCJ consumption; 2/12 increased with PLA. 356 
A main effect for time (F(1, 11) = 7.720; P = 0.018, 
2
partial  = 0.41) only was observed for 357 
HOMA2-β with pre-post 6 days supplementation data. Post-hoc analysis highlighted greater 358 
pancreatic β-cell function post-supplementation (PLA: 152 ± 49%, MTCJ: 148 ± 56%) 359 
compared to pre-supplementation (PLA: 131 ± 43%, MTCJ: 132 ± 53%)  (P = 0.018, d = 0.37). 360 
No significant main effects were found on change from pre-bolus data for HOMA2-β (P > 361 
0.05). 362 
***Figure 3 near here***363 
3.1.4. Lipids 364 
Reponses to total cholesterol after 6 days supplementation showed significant main effects for 365 
time (F(1, 11) = 5.097; P = 0.045, 
2
partial  = 0.32) and interaction (F(1, 11) = 5.700; P = 0.036, 366 
2
partial  = 0.34) (Figure 4). Post-hoc identified a significant difference between PLA and MTCJ 367 
at pre-supplementation (P = 0.030; d = 2.14). Total cholesterol was significantly (t(11) = 3.724; 368 
P = 0.003, d = 0.39) lower post-supplementation (4.1 ± 1.0 mmol.L-1) compared to pre-369 
supplementation (4.5 ± 1.0 mmol.L-1) with MTCJ. 370 
A significant interaction effect was observed for HDL (F(1, 11) = 5.212; P = 0.043, 
2
partial  = 371 
0.32) and LDL (F(1, 11) = 7.004; P = 0.023, 
2
partial  = 0.39) after 6 days supplementation (Figure 372 
4). A significant difference between PLA and MTCJ was found at post-supplementation time 373 
point for HDL (P = 0.049, d = 0.42), while pre-supplementation was significantly different for 374 
LDL (P = 0.031, d = 0.42). LDL was significantly (t(11) = 3.681; P = 0.004, d = 0.21) lower 375 
post-supplementation (2.71 ± 1.62 mmol.L-1) compared to pre-supplementation (3.07 ± 1.69 376 
mmol.L-1) with MTCJ. Individual responses showed 6/12 participants increased HDL 377 
concentrations after 6 days MTCJ supplementation, whereas 2/12 increased with PLA. 378 
Moreover, 10/12 participants reduced LDL concentrations after MTCJ supplementation, 379 
compared to 5/12 with PLA. 380 
After 6 days supplementation, an interaction effect was observed for TC:HDL (F(1, 11) = 13.681; 381 
P = 0.004, 
2
partial  = 0.55) (Figure 4). Post-hoc comparisons showed PLA to be significantly 382 
higher than MTCJ at pre-supplementation time point (P = 0.011; d = 2.67). TC:HDL ratio was 383 
significantly (t(11) = 2.690; P = 0.021, d = 0.30) lower post-supplementation (3.11 ± 1.13 384 
mmol.L-1) compared to pre-supplementation (3.47 ± 1.28 mmol.L-1) with MTCJ. No significant 385 
interaction or main effects for condition and time were observed for triglycerides with pre-post 386 
6 days supplementation data (P > 0.05) (Table 2).  387 
Change from pre-bolus data showed a main effect of time (F(2, 22) = 11.649; P < 0.001, 
2
partial  388 
= 0.51) and a tendency for a significant interaction (F(2, 22) = 3.148; P = 0.063, 
2
partial  = 0.22) 389 
for triglyceride concentrations (Table 2). Change from pre-bolus data indicated a significant 390 
main effect of condition (F(1, 11) = 5.874; P = 0.034, 
2
partial  = 0.35) and time (F(2, 22) = 4.110; 391 
P = 0.030, 
2
partial  = 0.27) for LDL, with higher LDL concentrations at pre-supplementation 392 
compared to post-supplementation (P = 0.034; d = 0.08) (Table 2). No main effects for 393 
condition, time or interaction were found for HDL or TC:HDL ratio with change from pre-394 
bolus data (P > 0.05) (Table 2). 395 
***Figure 4 near here***396 
3.1.5. ACE 397 
ACE did not show any main effects for condition, time or interaction with pre-post 6 days 398 
supplementation data or change from pre-bolus data (Table 2) (P > 0.05). 399 
3.2. Cardiac Haemodynamics 400 
No main effects for condition, time or interaction were detected for SBP, DBP, MAP, HR, SV, 401 
CO and TPR (P > 0.05) for pre-post 6 days supplementation data (Table 3).  402 
There were no main effects for condition, time or interaction on change from pre-bolus data 403 
with DBP, MAP, HR, SV, CO and TPR (P > 0.05) (Table 3). A tendency towards significance 404 
was detected for the interaction (F(5, 55) = 2.128; P = 0.076, 
2
partial  = 0.16) with SBP. Individual 405 
responses for the change from pre-bolus to 2-hours post-bolus showed 4/12 participants 406 
decreased SBP with PLA (4 ± 13 mmHg), while 10/12 participants reduced with MTCJ (-7 ± 407 
10 mmHg). 408 
***Table 3 near here***409 
3.3. 24-hour ABPM 410 
A significant interaction (F(1, 11) = 9.941; P = 0.016, 
2
partial  = 0.59) and main effect for 411 
condition (F(1, 11) = 7.916; P = 0.026, 
2
partial  = 0.53) was observed for mean 24-hour SBP 412 
after 7 days of supplementation (Figure 5). A significant difference between PLA and MTCJ 413 
was identified with post-hoc analysis at the post-supplementation time point (P = 0.024; d = 414 
0.44). Individual responses showed 11/12 participants reduced 24-hour SBP after 7 days MTCJ 415 
supplementation, compared to 2/12 with PLA. 416 
Likewise, mean 24-hour DBP only showed significant main effects for condition (F(1, 11) = 417 
12.321; P = 0.010, 
2
partial  = 0.64) and interaction (F(1, 11) = 12.789; P = 0.009, 
2
partial  = 0.65) 418 
(Figure 5). At pre-supplementation (P = 0.049; d = 0.14) and post-supplementation (P = 0.008; 419 
d = 0.66) time points, post-hoc demonstrated a significant difference between PLA and MTCJ. 420 
Individual responses showed 10/12 participants reduced mean 24-hour DBP after 7 days MTCJ 421 
supplementation, compared to 2/12 with PLA. 422 
A significant interaction (F(1, 11) = 6.236; P = 0.041, 
2
partial  = 0.47) and tendency towards 423 
significance for the main effect of condition (F(1, 11) = 5.122; P = 0.058, 
2
partial  = 0.42) was 424 
detected for mean 24-hour MAP (Figure 5). Post-hoc analysis indicated PLA was significantly 425 
higher than MTCJ at the post-supplementation time point (P = 0.010; d = 0.58). Individual 426 
responses showed 9/12 participants reduced mean 24-hour MAP after 7 days MTCJ 427 
supplementation, compared to 1/12 with PLA. A tendency towards a significant interaction 428 
effect (F(1, 11) = 3.995; P = 0.086, 
2
partial  = 0.36) was found for mean 24-hour PP. No main 429 
effects for time or condition were detected for mean 24-hour PP (P > 0.05).  430 
 431 
Mean day-time SBP demonstrated a tendency towards significance for the interaction (F(1, 11) 432 
= 4.499; P = 0.072, 
2
partial  = 0.39) and a significant main effect for condition only (F(1, 11) = 433 
6.507; P = 0.038, 
2
partial  = 0.48) (Table 4). Three of 12 participants were found to have lower 434 
mean day-time SBP with PLA after 7 days supplementation, whilst 11/12 participants were 435 
found to have lower mean day-time SBP with MTCJ. 436 
Significant main interaction (F(1, 11) = 5.725; P = 0.048, 
2
partial  = 0.45) and condition (F(1, 11) 437 
= 5.876; P = 0.046, 
2
partial  = 0.46) effects were observed for mean day-time DBP (Table 4). 438 
Pairwise comparisons for the interaction effect showed significantly higher mean day-time 439 
DBP with PLA compared to MTCJ at post-supplementation time point (P = 0.020; d = 0.67). 440 
Individual responses showed 8/12 participants had lower mean day-time DBP after 7 days 441 
MTCJ supplementation, compared to 2/12 with PLA. 442 
There were no significant main effects for condition, time or interaction with mean day-time 443 
MAP (P > 0.05) (Table 4). A main effect for time was observed for mean day-time PP (F(1, 11) 444 
= 13.661; P = 0.008, 
2
partial  = 0.66), with post-hoc showing pre-supplementation to be 445 
higher than post-supplementation (P = 0.008; d = 0.42) (Table 4). Analysis on night-time 446 
SBP, DBP, MAP and PP demonstrated no significant main effects for condition, time or 447 
interaction (P > 0.05) (Table 4). 448 
The day-night difference for SBP (F(1, 11) = 7.355; P = 0.030, 
2
partial  = 0.51) and PP (F(1, 11) = 449 
7.199; P = 0.031, 
2
partial  = 0.51) only showed a significant main effect for condition, where 450 
PLA was larger than MTCJ (Table 4). Day-night differences for DBP and MAP indicated no 451 
significant main effects for condition, time or interaction (P > 0.05) (Table 4). 452 
***Figure 5 and Table 4 near here***453 
3.4. Pulse Wave Analysis 454 
No significant main effects for condition, time or interaction were detected for aortic SBP, 455 
aortic DBP, AP, PP, AIx, AIx at HR75 and SEVR (P > 0.05) for pre-post 6 days 456 
supplementation data (Table 3). 457 
No main effects for condition, time or interaction (P > 0.05) were found on change from pre-458 
bolus data for aortic SBP. However, individual responses for the change from pre-bolus to 2-459 
hours post-bolus showed 4/12 participants decreased aortic SBP with PLA (3 ± 9 mmHg), 460 
while 9/12 participants responded with lower aortic SBP after consuming MTCJ (-4 ± 8 461 
mmHg). There were no main effects for condition, time or interaction on change from pre-462 
bolus data for aortic DBP, AP, PP, AIx and SEVR (P > 0.05) (Table 3). A main effect of 463 
condition was found for AIx at HR75 (F(1, 11) = 4.929; P = 0.048, 
2
partial  = 0.31). 464 
3.5. Resting Metabolic Rate 465 
No significant main effects for condition, time or the condition by time interaction were 466 
detected for resting EE after 6 days MTCJ consumption (P > 0.05). Significant interaction 467 
effects were found for resting RER (F(1, 11) = 10.045; P = 0.009, 
2
partial  = 0.48), fat oxidation 468 
rate (F(1, 11) = 9.394; P = 0.011, 
2
partial  = 0.46) and carbohydrate oxidation rate (F(1, 11) = 5.644; 469 
P = 0.037, 
2
partial  = 0.34) between PLA and MTCJ after 6 days supplementation (Table 3). 470 
Post-hoc identified a significant difference between conditions at pre-supplementation time 471 
point for fat (P = 0.024; d = 0.68) and carbohydrate (P = 0.027; d = 0.81) oxidation rates. RER 472 
was significantly (t(11) = 2.823; P = 0.017, d = 0.70) lower post-supplementation (0.83 ± 0.04) 473 
compared to pre-supplementation (0.86 ± 0.04) with MTCJ. 474 
A significant main effect for time only was observed for resting EE (F(5, 55) = 2.788; P = 0.026, 475 
2
partial  = 0.20), RER (F(5, 55) = 43.536; P < 0.001, 
2
partial  = 0.80), fat (F(5, 55) = 14.183; P < 476 
0.001, 
2
partial  = 0.56) and carbohydrate (F(5, 55) = 15.936; P < 0.001, 
2
partial  = 0.59) oxidation 477 
on change from pre-bolus data (Table 3). 478 
4. Discussion 479 
This study examined blood-based and functional cardio-metabolic responses to short-term 480 
continuous (6 days) MTCJ supplementation and acute on short-term supplementation (acute 481 
bolus on 7th day following 6 days supplementation) of MTCJ in humans with MetS. The 482 
hypotheses of the study were partially accepted as individual responses suggested a tendency 483 
for potential improvements in the underlying pathophysiology of MetS, insulin resistance and 484 
sensitivity, after 6 days MTCJ consumption compared to PLA. Findings also indicated a 485 
significant reduction in glucose, total cholesterol and LDL concentrations with concomitant 486 
lower resting RER values after 6 days MTCJ consumption compared to PLA. Of great clinical 487 
relevance, MTCJ significantly improved 24-hour BP after 7 days consumption compared to 488 
PLA. However, the present study was unable to confirm the hypothesis that the anti-489 
hypertensive effect of MTCJ was due to changes in ACE concentrations. 490 
4.1. Metabolic Responses 491 
The present study showed MTCJ significantly reduced fasting glucose by 9% (-0.51 mmol.L-492 
1) after 6 days consumption, highlighting the potential efficacy of tart cherries to improve 493 
glycaemic function in insulin resistant individuals. Similarly, Ataie‐ Jafari et al. (2008) [27] 494 
reported an 8% (-0.7 mmol.L-1) reduction in fasting glucose and reduced HbA1c after 6 weeks 495 
tart cherry concentrate consumption in individuals with T2D. This study therefore suggests 496 
short-term supplementation may be as effective, but more practical and economically viable 497 
than prolonged supplementation strategies. 498 
After 6 days supplementation of MTCJ compared to PLA, there was a tendency for lower 499 
fasting insulin concentrations with concomitant normal fasting glucose concentrations. As 500 
mentioned by Willems et al. (2017) [12] with anthocyanin-rich NZBP, this may be suggestive 501 
of improved insulin sensitivity. However, HOMA2-%S was not found to be higher after 6 days 502 
MTCJ intake, although 9/12 participants did report a physiological increase in HOMA2-%S. 503 
Hence, with a larger sample size these findings may corroborate the physiological theory 504 
postulated that MTCJ may confer improvements in insulin sensitivity. Willems et al. (2017) 505 
[12] demonstrated a reduction in fasting insulin by 14.3% (-9.5 pmol.L-1) after 7 days 506 
consumption of NZBP and attributed this to heightened insulin sensitivity. Similarly, fasting 507 
insulin was reduced by 9.3% (-12.42 pmol.L-1) after 6 days consumption of MTCJ and reduced 508 
by 14% when comparing against placebo. Individual responses suggested insulin resistance 509 
tended to be improved after 6 days intake of MTCJ (HOMA2-IR change: -0.27 ± 0.56) 510 
compared to PLA (HOMA2-IR change: 0.48 ± 0.78), likewise Willems et al. (2017) [12] 511 
indicated 7 days anthocyanin-rich NZBP consumption tended to improve insulin resistance. 512 
Together, these findings highlight short-term continuous supplementation of cyanidin- (MTC) 513 
and delphinidin-rich (NZBP) interventions may have the capacity to improve insulin 514 
sensitivity/resistance in healthy [12] and MetS populations. However, larger datasets are 515 
required to justify these initial observations. Moreover, it remains to be seen how long any 516 
beneficial effects last, and whether intermittent supplementation for 6-7 days over a longer 517 
duration may be a more physiologically effective, ecologically valid and economically viable 518 
supplementation strategy. As fasting glucose and insulin responses were complementary of 519 
each other, the change after 6 days indicates MTCJ may normalise glucoregulatory control 520 
[10]. This may be of significance when considering insulin resistance is the underlying cause 521 
of impaired cardio-metabolic function in humans with MetS. 522 
4.2. Lipid Responses 523 
This study suggests MTCJ may improve aspects of the lipid profile in individuals with MetS. 524 
The significant reduction in total cholesterol found in the present study agrees with findings 525 
from Ataie‐ Jafari et al. (2008) [27], but similar responses were not observed in other studies 526 
providing tart cherries [28,29], although a trend for lower concentrations was observed in MetS 527 
adults [30]. The reduction in total cholesterol with MTCJ may be explained by lower LDL 528 
fractions after 6 days supplementation. Similarly, reductions in LDL were reported in subjects 529 
with elevated baseline LDL after tart cherry juice consumption [27,29]; aligning with findings 530 
from other human trials supplementing anthocyanin-rich interventions that hyperlipidaemia is 531 
a prerequisite to observe improvements [31]. Clinically, LDL responses after 6 days MTCJ 532 
consumption may correspond to an 8% relative risk reduction of major vascular events [32].  533 
Bing sweet cherry consumption had no effect on TC:HDL ratio in healthy adults [33]. In the 534 
present study, TC:HDL ratio was found to be lower after 6 days consumption of MTCJ and 535 
individual responses showed 10/12 participants with lower TC:HDL ratios after MTCJ 536 
supplementation compared to 1/12 participants with placebo. Furthermore, TC:HDL ratio was 537 
shown to be a good predictor of cardiovascular risk reduction when assessing interventions 538 
[34], thus improvements in TC:HDL after 6 days MTCJ ingestion highlight its clinical efficacy 539 
against cardiovascular events.  540 
4.3. Cardiovascular Responses 541 
The efficacy of sweet and tart cherry interventions on improving BP, particularly SBP, had 542 
been demonstrated numerous times in various populations [7,8,14,27,35], including MetS [13]. 543 
However, these studies used lab-based measurements which is clinically inferior to 24-hour 544 
ABPM [19,36]. Therefore, the present study was the first to demonstrate reductions in mean 545 
24-hour SBP, DBP and MAP after cherry supplementation in any population.  546 
A clinically significant reduction in mean 24-hour SBP was observed after 7 days MTCJ 547 
consumption (-5 mmHg); which would be associated with prevention of all-cause and 548 
cardiovascular mortality by 20% [37]. This finding adds greater clinical and biological 549 
relevance to the individual responses reported for acute SBP reductions in the present study, 550 
by Keane et al. (2016b) [8] and Desai et al. (2019) [13] after an acute, single-bolus of MTCJ. 551 
In this study, a reduction of 11 mmHg was observed after 6 days MTCJ consumption compared 552 
to PLA for acute SBP at 2-hours post-bolus. Comparative reductions of 8 mmHg were seen 553 
with 7 days blueberry juice consumption compared to PLA in individuals with pre- and stage 554 
1 hypertension [38], highlighting the efficacy of 6-7 days consumption of anthocyanin-rich 555 
juices (~270-314 mg.day-1 total anthocyanins). Importantly, the magnitude of acute SBP 556 
reduction with MTCJ was comparable to approved anti-hypertensive drugs, associated with 557 
harmful side effects [39]. Moreover, the 2 mmHg reduction in mean 24-hour DBP after 7 days 558 
MTCJ consumption would be associated with a risk reduction of coronary heart disease and 559 
stroke by 6 and 15%, respectively [40]. This response was facilitated by significant day-time 560 
DBP reductions with MTCJ, which has been shown to be a significant predictor of CVD, 561 
coronary heart disease and stroke [41]. Despite supplementing a similar daily anthocyanin 562 
dosage as the present study (270 mg.day-1), Stull et al. (2015) [20] reported no effect on 24-563 
hour BP after consuming anthocyanin-rich (290.3 mg.day-1 anthocyanins) blueberry smoothie 564 
for 6 weeks compared to PLA, in individuals with MetS. Hence the above literature supports 565 
the hypothesis that short-term, low-dose anti-oxidant supplementation derived from 566 
anthocyanins may be a more pragmatic method to induce clinically relevant improvements in 567 
lab-based and 24-hour BP. However, it should be noted that long-term supplementation of 568 
anthocyanin-rich interventions [31,42], including tart cherries [27,29], have been shown to 569 
reduce BP through overlapping but different mechanisms (increased arterial compliance and/or 570 
improved endothelial function) [43] to short-term supplementation. 571 
Aviram and Dornfeld (2001) [44] demonstrated reductions in SBP were correlated with 572 
significantly lower ACE activity after 2 weeks pomegranate juice consumption. Furthermore, 573 
Kirakosyan et al. (2018) [9] demonstrated 88.7% ACE inhibition in vitro, with MTC extract. 574 
However, in the present study, as no correlations were observed between serum ACE 575 
concentrations and changes in cardiovascular parameters, the hypotensive effects of MTCJ 576 
may not be explained by alterations in ACE concentrations. Yet, individual responses showed 577 
8/12 participants had lower ACE concentrations 6 days after MTCJ compared to 4/12 with 578 
PLA. The high inter-individual variation of ACE may contribute to the null results, particularly 579 
given the variation in age between participants. Hence, it is possible that the action of ACE 580 
may only be prominent in certain individuals, and other mechanisms such as increased arterial 581 
stiffness and endothelial dysfunction in older participants may contribute to elevated BP. 582 
Overall, MTCJ may still inhibit ACE and explain the hypotensive effects, however future 583 
research should assess this through ACE activity assays to accurately elucidate this mechanism 584 
of action. 585 
Despite the prospective nature of the study, a limitation would be the small sample size on 586 
which conclusions are based, therefore larger clinical trials are required assessing individuals 587 
with MetS, but also other clinical populations. Moreover, surrogate indices of pancreatic β-cell 588 
function, insulin resistance and sensitivity were used. Future work should consider using 589 
tolerance tests or hyperinsulinaemic-euglycaemic clamps to assess the efficacy of MTCJ on 590 
post-prandial responses, which provides more ecologically valid conclusions. A key strength 591 
of the study was the use of 24-hour ABPM as a clinically relevant measure of assessing the 592 
effect of MTCJ on blood pressure and subsequently cardiovascular risk. Another strength was 593 
the use of a dietary supplement made of a whole food; upholding ecological validity due to the 594 
simplicity of incorporating such an intervention into habitual diets. 595 
5. Conclusion 596 
The present study has provided novel findings and demonstrated clinically relevant 597 
improvements on aspects of cardio-metabolic function, emphasising the potential efficacy of 598 
MTCJ in preventing further cardio-metabolic dysregulation in an ‘at risk’ population. Of 599 
particular clinical relevance, 24-hour ABPM was significantly improved after 7 days MTCJ 600 
consumption. Further work is required to elucidate mechanisms for BP responses, but also 601 
other cardio-metabolic improvements shown here. It remains to be seen how long the 602 
reductions in 24-hour BP last with MTCJ, however with further research MTCJ could perhaps 603 
replace or be used as an adjuvant to anti-hypertensive drugs in the future. Nevertheless, the 604 
evidence presented is promising for individuals with elevated cardiovascular risk particularly, 605 
pre-hypertension. Future clinical trials with larger sample sizes assessing individuals with 606 
MetS, but also other clinical populations are required to affirm these conclusions. 607 
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 754 
Tables and Figures 755 
756 
Table 1A. Selected baseline characteristics obtained during screening (n = 12). 
Characteristics Mean ± SD 
Fasting Total Cholesterol (mmol.L-1) 4.17 ± 1.21 
24-hour SBP (mmHg) 128 ± 10 
24-hour DBP (mmHg) 77 ± 8 
Fasting Insulin (pmol.L-1) 118.99 ± 68.14 
HOMA2-IR (AU) 2.2 ± 1.4 
HOMA2-β (%) 137.9 ± 49.5 
HOMA2-%S (%) 63.2 ± 40.5 
ACE (pg.mL-1) 8627 ± 8702 
Table 1B. Individual baseline characteristics of MetS criteria obtained during screening (n = 12). 757 
 *Denotes meeting MetS criteria for respective characteristic. (F) denotes female participant. (M) denotes male participant. 758 
 759 
  Participant 




101.0 ± 19.3 102* 125* 80* 85 125.4* 119* 88* 82* 74.5 100* 104* 127* 
Fasting Glucose 
(mmol.L-1) 




1.6 ± 0.3 1.7* 2.0* 1.2 1.8* 2.2* 1.3 1.7* 1.9* 1.8* 1.7* 1.1 1.3 
Fasting HDL 
(mmol.L-1) 
1.41 ± 0.32 1.95 1.32 1.38 1.69 1.09 1.31 1.19* 1.58 1.88 1.52 1.01* 1.01* 
SBP (mmHg) 135 ± 16 122 131* 131* 158* 149* 161* 104 131* 136* 135* 131* 125 
DBP (mmHg) 77 ± 8 66 75 88* 91* 85* 70 75 70 85* 79 69 76 
 760 
 761 
Figure 1. CONSORT flow diagram of the participants recruited, screened, tested, analysed and 762 
excluded during the course of the study. 763 
 764 
 765 
Assessed for eligibility (n = 39) 
Excluded (n = 24) 
   Not meeting inclusion criteria (n = 23) 
   Declined to participate (n = 1) 
Analysed (n = 12) 
 
Allocated to Placebo intervention (n = 8) 
 Received allocated intervention (n = 7) 
 Not received allocated intervention (n = 1) 





Randomised (n = 15) 
Enrolment 
Allocated to MTCJ intervention (n = 7) 
 Received allocated intervention (n = 7) 
 Not received allocated intervention (n = 0) 
Allocation 
2 
Allocated to Placebo intervention (n = 7) 
 Received allocated intervention (n = 6) 
 Not received allocated intervention (n = 1) 
(Participant dropped out for personal reasons) 
Allocated to MTCJ intervention (n = 7) 
 Received allocated intervention (n = 6) 
 Not received allocated intervention (n = 1) 
(Participant dropped out for personal reasons) 
 
Figure 2. (A) Schematic representation of the overall study design. (B) Schematic 766 






















*Denotes significant difference between conditions at respective time point. ^Denotes significant difference between pre- and 6 days post-787 
supplementation time points for MTCJ. §Denotes significant difference between conditions at post-supplementation time point. $Denotes 788 
significant main effect for time with post-hoc identifying differences between 1-hour and both 3-hours and 5-hours post-bolus (P < 0.05).789 
 Table 2. Mean ± SD absolute raw data for blood-based biomarkers per treatment condition.  





Post 6 days 
Supplementation 
1 hr 3 hr 5 hr 
Glucose$ 
(mmol.L-1) 
PLA 5.33 ± 0.18* 5.36 ± 0.25 5.83 ± 0.24 5.28 ± 0.13 5.49 ± 0.19 
MTCJ 5.90 ± 0.86^ 5.39 ± 0.23 5.88 ± 0.24 5.13 ± 0.22 5.14 ± 0.13 
Insulin$ 
(pmol.L-1) 
PLA 109.55 ± 68.95* 136.59 ± 72.18 146.29 ± 76.90 104.26 ± 59.70 97.77 ± 64.19 
MTCJ 138.39 ± 72.28 125.96 ± 65.57 153.23 ± 87.21 97.43 ± 54.57 93.76 ± 65.29 
Triglycerides$ 
(mmol.L-1) 
PLA 1.2 ± 0.1 1.3 ± 0.1 1.4 ± 0.1 1.5 ± 0.1 1.6 ± 0.1 




PLA 3.99 ± 0.22* 4.03 ± 0.33 4.17 ± 0.34 4.23 ± 0.24 4.25 ± 0.19 
MTCJ 4.55 ± 0.30^ 4.14 ± 0.41 4.17 ± 0.39 4.03 ± 0.45 3.96 ± 0.17 
HDL 
(mmol.L-1) 
PLA 1.43 ± 0.01 1.30 ± 0.01 1.30 ± 0.02 1.27 ± 0.02 1.27 ± 0.02 
MTCJ 1.39 ± 0.03 1.40 ± 0.02§ 1.40 ± 0.03 1.40 ± 0.01 1.36 ± 0.03 
LDL 
(mmol.L-1) 
PLA 2.39 ± 0.21 2.65 ± 0.31 2.99 ± 0.37 3.14 ± 0.30 3.30 ± 0.28 
MTCJ 3.07 ± 0.32^ 2.71 ± 0.46 2.77 ± 0.35 2.91 ± 0.36 2.83 ± 0.31 
ACE 
(pg.mL-1) 
PLA 8706 ± 8748 9334 ± 10363 10609 ± 12780 10743 ± 12267 10538 ± 11417 
MTCJ 10161 ± 11474 9127 ± 10915 9548 ± 11486 9460 ± 11385 9150 ± 11521 
 790 
Figure 3. (A) Glucose, (B) Insulin, (C) HOMA2-IR, (D) HOMA2-%S and (E) HOMA2-β responses before and after supplementation of PLA and MTCJ. 791 
Bar graphs depict mean (±SD) group values for each condition, pre and post 6 days supplementation. Lines depict individual responses for all 12 participants. 792 
*Denotes significant difference between conditions at respective time point. ^Denotes significant difference between pre- and post-supplementation time 793 
points for MTCJ. 794 
Table 3. Mean ± SD absolute raw data for cardiac haemodynamic, PWA and RMR parameters per treatment condition. 
     Post-bolus Time Points 
  Pre-6 days 
Suppl. 
Post 6 days 
Suppl. 
30 minutes 1 hr 2 hr 3 hr 4 hr 5 hr 
Brachial SBP 
(mmHg) 
PLA 127 ± 16 128 ± 17 133 ± 13 130 ± 14 132 ± 19 132 ± 19 128 ± 10 129 ± 13 







75 ± 10 
 
74 ± 7 
 
76 ± 8 
 
72 ± 5 
 
74 ± 5 
 
73 ± 8 
 
74 ± 7 
 
75 ± 5 





98 ± 12 
 
93 ± 10 99 ± 9 94 ± 8 97 ± 8 96 ± 10 97 ± 10 97 ± 9 
MTCJ 98 ± 12 93 ± 9 95 ± 4 96 ± 7 93 ± 6 95 ± 8 95 ± 8 96 ± 8 
          
HR  
(beats.min-1) 
PLA 65 ± 12 67 ± 14 68 ± 16 67 ± 16 66 ± 17 66 ± 16 65 ± 15 65 ± 5 





6.85 ± 2.46 
 
6.64 ± 2.37 6.86 ± 2.46 7.05 ± 2.74 7.00 ± 4.07 7.10 ± 3.23 6.02 ± 2.22 6.44 ± 2.03 





104 ± 26 
 
98 ± 21 100 ± 22 104 ± 21 101 ± 34 105 ± 23 103 ± 26 98 ± 17 






1.03 ± 0.48 
 
0.91 ± 0.23 0.96 ± 0.33 0.89 ± 0.27 1.04 ± 0.44 0.93 ± 0.32 1.09 ± 0.38 0.99 ± 0.29 





124 ± 12 
 
119 ± 15 120 ± 12 119 ± 12 121 ± 14 124 ± 13 119 ± 15 120 ± 13 
MTCJ 124 ± 15 120 ± 15 121 ± 14 118 ± 14 116 ± 13 120 ± 14 119 ± 15 120 ± 13 
 
         
Aortic DBP 
(mmHg) 
PLA 80 ± 7 80 ± 9 82 ± 11 80 ± 11 83 ± 9 84 ± 11 84 ± 8 83 ± 7 
MTCJ 81 ± 9 79 ± 10 79 ± 9 80 ± 9 78 ± 8 83 ± 10 81 ± 7 80 ± 8 
AP (mmHg) PLA 11 ± 6 9 ± 6 8 ± 5 7 ± 5 9 ± 6 11 ± 8 9 ± 6 10 ± 8 





38 ± 9 
 
35 ± 11 38 ± 7 39 ± 7 38 ± 7 39 ± 13 35 ± 8 37 ± 10 






26 ± 13 
 
23 ± 12 
 
23 ± 12 
 
24 ± 12 
 
25 ± 13 
 
26 ± 15 
 
26 ± 14 
 
27 ± 14 
MTCJ 25 ± 14 24 ± 12 24 ± 14 24 ± 15 22 ± 14 23 ± 14 24 ± 14 26 ± 14 
AIx at HR75 (%)* 
PLA 
 
22 ± 10 
 
19 ± 11 20 ± 11 21 ± 12 21 ± 11 22 ± 12 23 ± 11 23 ± 12 




180 ± 30 
 
192 ± 36 187 ± 37 189 ± 35 192 ± 39 194 ± 43 197 ± 39 191 ± 37 
MTCJ 183 ± 39 178 ± 25 175 ± 29 177 ± 25 187 ± 40 189 ± 33 181 ± 29 177 ± 25 
Resting EE$ 
(kcal.day-1) 
PLA 1835 ± 509 1847 ± 437 1895 ± 397 1890 ± 360 1835 ± 411 1827 ± 394 1785 ± 394 1785 ± 356 
MTCJ 1793 ± 572 1794 ± 489 1871 ± 467 1892 ± 408 1781 ± 439 1795 ± 459  1790 ± 443 1865 ± 451 
 




PLA 0.85 ± 0.04 
 
0.86 ± 0.06 
 
0.96 ± 0.10 
 
0.93 ± 0.08 
 
0.87 ± 0.08 
 
0.84 ± 0.08 
 
0.82 ± 0.08 
 
0.81 ± 0.05 




PLA 0.08 ± 0.04 0.06 ± 0.03 0.04 ± 0.07 0.08 ± 0.09 0.06 ± 0.04 0.08 ± 0.05 0.08 ± 0.04 0.09 ± 0.04 




PLA 0.14 ± 0.08 0.20 ± 0.13 0.25 ± 0.15 0.16 ± 0.20 0.18 ± 0.08 0.14 ± 0.08 0.13 ± 0.09 0.12 ± 0.09 
MTCJ 0.22 ± 0.12# 0.17 ± 0.08 0.33 ± 0.11 0.30 ± 0.14 0.21 ± 0.08 0.18 ± 0.09 0.14 ± 0.08 0.13 ± 0.05 
*Denotes significant main effect of condition for change from pre-bolus data. ^Denotes significant main effect for interaction between PLA and MTCJ pre 795 
and post 6 days supplementation. #Denotes significant difference between conditions at pre-supplementation time point. §Denotes significant difference 796 
between pre-supplementation and post-supplementation time points for MTCJ. $Denotes significant main effect of time on change from post 6 days 797 
supplementation data. 798 
 799 
Figure 5. (A) Mean 24-hour SBP, (B) Mean 24-hour DBP and (C) Mean 24-hour MAP responses before and after supplementation of PLA and MTCJ. Bar 800 
graphs depict mean (±SD) group values for each condition, pre and post 7 days supplementation. Lines depict individual responses for all 12 participants. 801 
^Denotes significant difference between conditions at pre-supplementation time point. *Denotes significant difference between conditions at post-802 
supplementation time point. 803 
Table 4. Mean ± SD day-time, night-time and day-night differences from 24-hour 





PLA 132 ± 8 133 ± 8 
MTCJ 132 ± 9 127 ± 11 
Day DBP$ 
(mmHg) 
PLA 79 ± 7 81 ± 7^ 
MTCJ 79 ± 6 76 ± 6 
Day MAP 
(mmHg) 
PLA 92 ± 8 97 ± 7 







53 ± 6 
 
51 ± 5 
MTCJ 53 ± 5 50 ± 8 
Night SBP 
(mmHg) 
PLA 113 ± 13 117 ± 7 
MTCJ 117 ± 12 117 ± 13 
Night DBP 
(mmHg) 
PLA 68 ± 9 69 ± 8 
MTCJ 69 ± 10 68 ± 8 
Night MAP 
(mmHg) 
PLA 82 ± 11 85 ± 7 
MTCJ 81 ± 14 84 ± 11 
Night PP 
(mmHg) 
PLA 46 ± 8 48 ± 5 
MTCJ 48 ± 7 49 ± 7 
D/N SBP* 
(mmHg) 
PLA 19 ± 12 16 ± 6 
MTCJ 15 ± 10 10 ± 8 
D/N DBP 
(mmHg) 
PLA 11 ± 8 12 ± 8 
MTCJ 10 ± 9 9 ± 7 
D/N MAP 
(mmHg) 
PLA 10 ± 8 13 ± 7 
MTCJ 11 ± 11 10 ± 9 
D/N PP* 
(mmHg) 
PLA 7 ± 7 4 ± 4 
MTCJ 5 ± 5 1 ± 3 
D/N (Day/Night Difference). *Denotes significant main effect for condition. §Denotes significant main effect for 804 
time. $Denotes significant main effect for interaction. ^Denotes significant difference between conditions at 805 
corresponding time point. 806 
 807 
